Get the Daily Brief
Latest Biotech News
Boehringer Ingelheim’s Hernexeos Gains Accelerated FDA Nod for Lung Cancer
Boehringer Ingelheim secured accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted therapy for adults with advanced non-small cell lung cancer harboring HER2 tyrosine...
Microbiome Influences Immune Development and Chronic Pain Conditions
Emerging research highlights the profound role of the microbiome in shaping human health. Newborn immune system maturation is influenced by breastmilk antibodies, particularly IgA, which modulate...
Biotech Industry Navigates Funding and Market Pressures Amidst Innovation
Biotech firms face a complex landscape marked by capital constraints and evolving regulatory environments. Standard BioTools reported a 3% revenue decline in Q2 2025 despite consumables growth,...
AI and Machine Learning Enhance Medical Diagnostics and Emergency Care
Artificial intelligence continues to accelerate innovations in healthcare delivery and diagnostics. Mount Sinai researchers developed AI models that predict hospital emergency admissions earlier...
Insights into Brain Function and Movement Disorders from Animal Models
Recent neuroscience studies are uncovering mechanisms underlying motor control and brain aging. Harvard researchers demonstrated that basal ganglia in rats use distinct neural codes for innate...
Boehringer Ingelheim Lung Cancer Drug FDA Nod: Hernexeos Clears Accelerated Approval
Boehringer Ingelheim's oral HER2-targeted drug, Hernexeos (zongertinib), received accelerated FDA approval for advanced non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase...
IO Biotech Cancer Vaccine Phase 3 Trial Narrowly Misses Endpoint But FDA Filing Planned
IO Biotech’s therapeutic cancer vaccine Cylembio combined with Merck’s Keytruda failed to meet the primary endpoint in a pivotal Phase 3 trial for unresectable or metastatic melanoma, narrowly...
Novartis Secures Dual Phase 3 Wins with Ianalumab in Sjögren’s Syndrome
Novartis announced positive results from two Phase 3 studies evaluating ianalumab, a B-cell-depleting antibody targeting BAFF-R, in Sjögren’s syndrome. Both trials met their primary endpoints,...
Tahoe Therapeutics Raises $30 Million to Build Billion-Cell AI Training Dataset
Tahoe Therapeutics secured $30 million in funding to contribute to the global effort of sequencing one billion cells. This initiative aims to create comprehensive virtual cell models to enhance...
Advances in Pediatric Cancer and Immunotherapy Biomarkers and Therapies
Researchers made strides in pediatric oncology and immunotherapy with several developments: A gene network and AI-driven study identified novel prognostic biomarkers in neuroblastoma, facilitating...
Biotech Industry Market Sentiment: Real Estate Slump and Funding Challenges in Boston
The Greater Boston life sciences sector is experiencing a significant oversupply crisis with 17 million square feet of available lab space and a vacancy rate near 30%, driven by speculative...
Vinay Prasad's Return to FDA’s CBER Amid Leadership Turmoil
Vinay Prasad was reinstated as director of the FDA's Center for Biologics Evaluation and Research (CBER) just two weeks after his removal, following a campaign that criticized his previous stances...
Emerging Technologies in Electron Tomography and Microscopy Enhance Material and Medical Research
Innovations in microscopy and electron tomography promise to accelerate research. A new rapid, automated multiscale electron tomography technique optimizes visualization of sensitive materials...
Cancer Center and Researchers Highlight Long-Term Health in Childhood Cancer Survivors
Collaborative research between The University of Texas at Arlington and City of Hope focuses on long-term health challenges faced by childhood cancer survivors, emphasizing the role wearable...
Novel Heat-Free Fruit Dehydration Technology Promises Sustainability in Food Preservation
Researchers have developed an innovative fruit dehydration method that operates at room temperature using controlled atmospheric pressure and food-safe calcium chloride, eliminating the...
Novartis Scores Double Phase 3 Wins in Sjögren’s Syndrome
Novartis has announced successful results from two Phase 3 trials of its antibody drug ianalumab in Sjögren’s syndrome, marking the first global studies demonstrating statistically significant...
IO Biotech’s Skin Cancer Vaccine Narrowly Misses Phase 3 Endpoint; FDA Path Planned
IO Biotech’s cancer vaccine Cylembio, tested in combination with Merck’s Keytruda for unresectable or metastatic melanoma, narrowly failed to meet its primary progression-free survival endpoint in...
Thermo Fisher Secures FDA Approval for Lung Cancer Companion Diagnostic
Thermo Fisher Scientific has obtained FDA approval for its Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS®, a tyrosine kinase inhibitor targeting...
Exact Sciences Buys Freenome’s Colorectal Cancer Blood Test Rights
Exact Sciences has acquired U.S. rights to Freenome’s colorectal cancer blood test for $75 million upfront, positioning itself against market rival Guardant Health in the liquid biopsy segment....
Canaccord Genuity Downgrades Quanterix Amid Integration Challenges
Investment bank Canaccord Genuity downgraded Quanterix shares from Buy to Hold, lowering the price target to $5 following disappointing Q2 2025 revenues and uncertainties in the integration of...